Patent ID: 11944617
Assignee: CORCEPT THERAPEUTICS INCORPORATED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 10:
11. The method of claim 1, wherein the first, second, and third effective doses of relacorilant and the single agent and effective reduced doses of paclitaxel are administered according to a 28-day schedule, wherein said single agent dose and said effective reduced dose of paclitaxel are each in the form of nab-paclitaxel, and wherein the effective reduced dose of nab-paclitaxel is a dose of between about 60 mg/m2 and about 96 mg/m 2 of nab-paclitaxel administered by intravenous infusion on days 1, 8 and 15 of each 28-day cycle.